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Polygenic risk of ischemic stroke is
associated with cognitive ability
ABSTRACT
Objectives:We investigated the correlation between polygenic risk of ischemic stroke (and its sub-
types) and cognitive ability in 3 relatively healthy Scottish cohorts: the Lothian Birth Cohort 1936
(LBC1936), the Lothian Birth Cohort 1921 (LBC1921), and Generation Scotland: Scottish Fam-
ily Health Study (GS).
Methods: Polygenic risk scores for ischemic stroke were created in LBC1936 (n 5 1005),
LBC1921 (n 5 517), and GS (n 5 6,815) using genome-wide association study summary data
from the METASTROKE collaboration. We investigated whether the polygenic risk scores corre-
late with cognitive ability in the 3 cohorts.
Results: In the largest cohort, GS, polygenic risk of all ischemic stroke, small vessel disease
stroke, and large vessel disease stroke, but not cardioembolic stroke, were correlated with both
fluid and crystallized cognitive abilities. The highest correlation was between a polygenic risk
score for all ischemic stroke and general cognitive ability (r 5 20.070, p 5 1.95 3 1028). Few
correlations were identified in LBC1936 and LBC1921, but a meta-analysis of all 3 cohorts
supported the correlation between polygenic risk of ischemic stroke and cognitive ability.
Conclusions: The findings from this study indicate that even in the absence of stroke, being at
high polygenic risk of ischemic stroke is associated with lower cognitive ability. Neurology®
2016;86:611–618
GLOSSARY
CE 5 cardioembolic; gf 5 general fluid; GS 5 Generation Scotland: Scottish Family Health Study; GWAS 5 genome-wide
association study; LBC1921 5 Lothian Birth Cohort 1921; LBC1936 5 Lothian Birth Cohort 1936; LVD 5 large vessel
disease; MHT 5 Moray House Test; NART 5 National Adult Reading Test; SNP 5 single-nucleotide polymorphism; SVD 5
small vessel disease.
The common cause theory of aging predicts that a proportion of the variance in both age-related
cognitive and physical decline is attributable to common biological processes.1 Exploring the
genetic links between cognitive function and diseases, such as ischemic stroke, may provide
insight. Risk factors for cognitive decline and ischemic stroke overlap.1,2 Low cognitive ability in
youth portends a greater risk of stroke in later life.3,4 Cognitive ability in later life is determined
by cognitive ability in youth5 and rate of cognitive decline.
With the exception of an association between APOE and cognitive ability in later life and age-
related cognitive decline,6,7 few individual genes have reliably been associated with variance in
normal cognitive ability. However, Genome-wide Complex Trait Analyses indicates that 29%
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to 50% of the variance in cognition measured
at a single time8,9 and about 24% of the
variance in lifetime cognitive change10 can be
attributed to common genetic variants. Heri-
tability, calculated from genome-wide single-
nucleotide polymorphism (SNP) data, is
estimated at 38% for all ischemic stroke,
40% for large vessel disease (LVD), 33% for
cardioembolic (CE) stroke, and 16% for small
vessel disease (SVD) stroke.11
We used genome-wide association study
(GWAS) summary data from the META-
STROKE Collaboration12 to generate poly-
genic risk scores for ischemic stroke and its
subtypes, SVD, LVD, and CE, in 3 Scottish
cohorts consisting of relatively healthy
participants—Generation Scotland: the Scot-
tish Family Health Study (GS), Lothian Birth
Cohort 1921 (LBC1921), and Lothian Birth
Cohort 1936 (LBC1936). We investigated
whether the polygenic risk scores predicted
cognitive ability/cognitive decline in the 3
cohorts.
METHODS Cohorts. LBC1936. LBC1936 comprises 1,091
(548 men) relatively healthy older participants, most of whom
took part in the Scottish Mental Survey of 1947, when they were
about 11 years old.13 At a mean age of 69.5 years (SD 0.8), they
were enrolled in a study designed to determine factors that influ-
ence cognitive aging.14,15 They took a number of cognitive and
physical tests including the Moray House IQ Test (MHT) No.
12 (a test of general cognitive function), which had been admin-
istered at age 11.
Medical history, including history of stroke, was recorded.
For this study, a general fluid (gf) cognitive ability score was
derived from principal components analysis of 6 Wechsler Adult
Intelligence Scale–III UK16 nonverbal subtests (Matrix Reason-
ing, Letter Number Sequencing, Block Design, Symbol Search,
Digit Symbol, and Digit Span Backward), as described previ-
ously.17 We also used MHT scores from age 11 and age 70 years,
and the National Adult Reading Test (NART),18 taken at age 70
years, as a measure of crystallized cognitive ability. A general
cognitive ability score was created as for the gf score plus the
addition of NART. Cognitive measures were adjusted for age
in days and sex before analysis. To obtain a measure of cognitive
aging from age 11 to age 70, gf was corrected for age-adjusted age
11 MHT scores, age, and sex.
LBC1921. LBC1921 comprises 550 (234 men) relatively
healthy older participants, most of whom took part in the Scottish
Mental Survey of 1932, when they were about 11 years old.19 At a
mean age of 79.1 years (SD 0.6), they were enrolled in a study
designed to determine factors that influence cognitive aging.5,15
They took a number of cognitive and physical tests including
the MHT, which had been administered at age 11. For this study,
a gf cognitive ability score was created from principal components
analysis of MHT, Raven Matrices, Logical Memory, and Verbal
Fluency, as described previously.8 We also used MHT scores
from age 11 and age 79 years and the NART18 from age 79 years.
A general cognitive ability score was created as for the gf score plus
the addition of NART. Cognitive measures were adjusted for age
in days and sex before analysis. To obtain a measure of cognitive
aging from age 11 to age 79, gf was corrected for age-adjusted age
11 MHT scores, age, and sex.
Generation Scotland: The Scottish Family Health Study.
GS is a family-structured, population-based cohort study.
Between 2006 and 2011, 24,084 participants were recruited in
Glasgow, Tayside, Ayrshire, Arran, and North East Scotland.
Participants range between 18 and 100 years old and there are up
to 4 generations per family.20,21
The cognitive tests applied were Logical Memory, Digit Sym-
bol, Verbal Fluency, and Mill Hill Vocabulary. The Logical
Memory test is a test of immediate verbal declarative memory
from the Wechsler22 Memory Scale–III UK. It involves immedi-
ate and delayed recall of a story with 25 elements that is read
aloud to the participant. The Digit Symbol test is from the
Wechsler Adult Intelligence Scale–III UK and measures speed
of information processing.16 The Verbal Fluency test23 measures
executive function. The participant has to name as many words as
possible beginning with the letters C, F, and L, and is given
1 minute for each letter. The sum of these 3 scores is taken as
the overall measure. A gf cognitive ability score was created from
principal components analysis of Logical Memory, Digit Symbol,
and Verbal Fluency. The Mill Hill Vocabulary test24 (Junior and
Senior Synonyms combined) was used as a measure of crystallized
cognitive ability. A general cognitive ability score was derived as
for the gf score plus the addition of the Mill Hill Vocabulary test.
Cognitive measures were adjusted for age in years and sex.
Medical history, including history of stroke, was recorded.
There were 10,000 white European participants, born in the
UK and with near complete phenotype data, selected for genotyp-
ing. In the present study, 6,815 unrelated participants (2,813
men), with a mean age of 55.5 years (SD 11.4), were analyzed.
DNA extraction. DNA was extracted from blood or buccal cells
using standard procedures at MRC Technology Edinburgh
(LBC1921) and the Wellcome Trust Clinical Research Facility
Genetics Core Edinburgh (LBC1936 and Generation Scotland).
Standard protocol approvals, registrations, and patient
consents. Ethical approval was attained for LBC1921 and
LBC1936 from the Lothian Research Ethics Committee and
for LBC1936 from Scotland’s Multicentre Research Ethics Com-
mittee and for Generation Scotland from the Tayside Research
Ethics Committee.
Creating stroke polygenic risk scores. DNA samples were
genotyped at the Wellcome Trust Clinical Research Facility using
the Illumina 610-Quadv1 array (San Diego) (LBC1936 and
LBC1921)8 or the Illumina HumanOmniExpressExome (San
Diego) (Generation Scotland). Individuals were excluded based
on relatedness (n 5 8 in LBC1936; n 5 1 in LBC1921; n 5
3,045 in GS), unresolved sex discrepancy (n 5 12 in LBC1936;
n5 1 in LBC1921; n5 14 in GS), low call rate (#0.95 n5 16
in LBC1936; n 5 5 in LBC1921; #0.97 n 5 117 in GS),
evidence of non-European descent (n 5 1 in LBC1936; n 5 2
in LBC1921), and pedigree mismatch (n5 8 in GS). SNPs were
used in the analyses if they had a call rate $0.98, a minor allele
frequency $0.01, and a Hardy-Weinberg equilibrium test with
p $ 0.001. The first 4 components from a multidimensional
scaling analysis of the SNP data were used as covariates in the
analyses to control for population stratification.
GWAS summary data for ischemic stroke and its subtypes
were obtained from the METASTROKE Consortium.12 Sum-
mary data included SNP name (rs number) and effect allele
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and size for imputed SNPs associated with all ischemic, SVD,
LVD, or CE stroke subtypes. The information was obtained for 5
different p value thresholds: ,0.8, ,0.5, ,0.1, ,0.05, and
,0.01. The ischemic stroke GWAS included 12,389 cases of
all subtypes, SVD 1,894 cases, LVD 2,167 cases, and CE
2,365 cases. The same 62,004 controls were used in each GWAS.
Twenty polygenic stroke risk scores (4 stroke phenotypes at 5 p
value thresholds) were thus created for each participant of
LBC1936, LBC1921, and GS as described in Ref. 25. A/T and
G/C SNPs, SNPs with a minor allele frequency,0.02, and SNPs
not present in METASTROKE were removed from LBC1936,
LBC1921, and GS. Pruning was performed to remove those in
linkage disequilibrium (r2 . 0.25 within a 200-SNP sliding win-
dow). Risk scores were then created in PLINK26 by summing the
product of each of the betas obtained from METASTROKE and
the number of effect alleles carried by the participant.
Statistical analyses. For all cohorts, partial correlations were
calculated between the 20 stroke polygenic risk scores and the
cognitive phenotypes described above. Covariates included the
number of nonmissing SNPs used to form the risk score, and 4
multidimensional scaling components. Where possible (in
LBC1936 and GS), individuals with a self-reported history of
stroke before the cognitive testing were removed from the
cognitive analyses. Random-effects meta-analyses of the gf,
general cognitive ability scores, and measures of crystallized
cognitive ability (NART in LBC1936 and LBC1921, and Mill
Hill Vocabulary in GS) were performed in R (MAc and
Metafor packages). An omnibus effect size and standard error
were derived and sample heterogeneity was investigated using
Cochran Q statistic, which calculated the sum of squared
deviations of each cohort’s effect size from the overall meta-
analytic estimate of significance.
RESULTS Fifty LBC1936 members (5%) and 127
GS members (1.9%) reported having had a stroke
before cognitive testing and were excluded from the
analyses. The number of SNPs that made up the pol-
ygenic risk scores is shown in table e-1 on the
Neurology® Web site at Neurology.org.
LBC1936. In LBC1936, 7 of 120 correlations between
cognitive test scores and polygenic risk scores for ische-
mic stroke (and its subtypes) reached a significance
level of p , 0.05 (table 1). All correlations indicated
that higher polygenic risk of ischemic stroke (and its
subtypes) was associated with higher cognitive ability.
LBC1921. In the relatively small LBC1921, there is a
general trend indicating that higher polygenic risk of
ischemic stroke (and its subtypes) is associated with
lower cognitive ability, with 4 of 120 reaching a sig-
nificance level of p , 0.05 (table 2).
GS. In GS, 71 of 120 correlations between cognitive
test scores and polygenic risk scores for ischemic
stroke (and its subtypes) reached a significance level
of p , 0.05 (table 3). All correlations between poly-
genic risk of all ischemic stroke, SVD stroke, and
LVD stroke and cognitive abilities indicated that
higher polygenic risk is associated with lower cogni-
tive abilities. Correlations between polygenic risk of
CE stroke and cognitive abilities indicated that higher
polygenic risk of CE stroke is associated with higher
cognitive abilities.
Meta-analysis: Cognition. In the meta-analysis, 14 of
60 correlations between cognitive test scores and
polygenic risk scores for ischemic stroke (and its
subtypes) reached a significance level of p , 0.05
(table e-2). Sample heterogeneity was indicated for
many of the crystallized and general cognitive
ability analyses. All correlations between polygenic
risk of all ischemic stroke, SVD stroke, and LVD
stroke and cognitive abilities indicated that higher
polygenic risk is associated with lower cognitive
abilities. Correlations between polygenic risk of CE
stroke and cognitive abilities indicated that higher
polygenic risk of CE stroke is associated with higher
cognitive abilities.
DISCUSSION In the largest (by 5- and 10-fold over
LBC1936 and LBC1921, respectively) of the cohorts
(GS), we found an association between higher
polygenic risk of all ischemic stroke and lower
cognitive ability. Correlations were generally higher
for general cognitive ability than the specific tests,
suggesting that the greatest influence is on general
cognitive ability. The lowest correlations were
identified for Verbal Fluency. We found similar
correlations between polygenic risk of SVD and
LVD stroke and cognitive ability, albeit with smaller
effects. For all ischemic and SVD stroke, the
polygenic risk scores containing more SNPs generally
correlated more strongly indicating that, as with
polygenic risk of schizophrenia,27 many SNPs with
very small effect sizes contribute to these risk scores.
High polygenic risk of CE stroke was not associated
with low cognition, perhaps because the mechanisms
leading to CE stroke may involve blood clotting rather
than neurovascular integrity, the former possibly
having less of an effect on cognition.
In GS, polygenic risk of all ischemic stroke was a
better predictor of cognitive ability than polygenic risk
of specific subtypes, and had greater power. We note
that the polygenic risk scores for all ischemic stroke
were created from a GWAS of .12,000 stroke cases,
whereas polygenic risk scores for each of the subtypes
were created using data from only approximately 2,000
cases. Also, although METASTROKE used the Trial
of Org 10172 in Acute Stroke Treatment (TOAST)28
to classify stroke subtypes, this is imprecise, depends
on detailed investigations for accurate phenotyping,
and therefore some cases may have been assigned
incorrectly. Undetected vascular events within
METASTROKE participants could also lead to incor-
rect classification of ischemic stroke subtype.
Correlations between cognitive scores and stroke
polygenic risk scores in the relatively small
LBC1921 were generally very similar to those in
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GS but the majority had p . 0.05. In LBC1936, the
majority of the correlations were in the opposite
direction to our hypothesis. It is possible that, as
the participants in LBC1936 are all aged about 70
years and still relatively healthy, they may, as a group,
have a low polygenic risk of stroke. Only 5% of the
cohort reported having experienced a stroke before
cognitive testing and these were removed before the
analyses. Including the 50 participants who had expe-
rienced a stroke made little difference to the results.
LBC1921 is also a relatively healthy older cohort.
However, incidence of stroke was not available and
it is possible that the trend toward a correlation
between cognitive ability at age 79 and stroke poly-
genic risk scores was driven by participants who had
experienced cognitive decline following a stroke.
Meta-analyses results also indicated that sample het-
erogeneity was present.
Both fluid and crystallized cognitive ability were
associated with polygenic risk of all ischemic, SVD,
and LVD stroke in GS. Although fluid cognitive abil-
ity tends to decline in later life, crystallized cognitive
ability, as measured in this study by tests of vocabu-
lary, remains relatively stable and is therefore a good
proxy measure of cognitive ability earlier in life.29 A
previous study with the LBC1936 cohort indicated
that higher cognitive ability measured at age 11 years
was associated with fewer white matter hyperinten-
sities at age 73 years.30 These data suggest that genetic
variants that predispose individuals to risk of ischemic
stroke or to risk of brain damage should they have an
ischemic trigger in later life, might act much earlier to
influence cognitive ability, possibly through influenc-
ing brain integrity or brain circulation. It is also pos-
sible that certain genes influence cognitive ability
through other pathways, for example, developmental
Table 1 Correlations and significance between ischemic stroke (and its subtypes) PGRS (calculated using different association p values) and
cognitive phenotypes in LBC1936
Stroke PGRS
MHT (age 11 yr)
(n 5 947), r, p
MHT (age 70 yr)
(n 5 945), r, p gf (n 5 940), r, p NART (n 5 953), r, p g (n 5 940), r, p
Cognitive change
(n 5 886), r, p
IS
p < 0.8 0.008, 0.81 0.061, 0.062 0.001, 0.97 0.075, 0.020a 0.016, 0.63 20.013, 0.70
p < 0.5 0.010, 0.76 0.061, 0.063 0.008, 0.81 0.076, 0.019a 0.021, 0.51 20.004, 0.90
p < 0.1 0.010, 0.75 0.061, 0.061 0.018, 0.58 0.055, 0.093 0.028, 0.40 0.002, 0.96
p < 0.05 0.022, 0.49 0.058, 0.076 0.035, 0.29 0.054, 0.098 0.043, 0.19 0.014, 0.68
p < 0.01 0.014, 0.66 0.033, 0.31 0.020, 0.55 0.026, 0.42 0.024, 0.47 20.022, 0.52
SVD
p < 0.8 20.016, 0.62 0.033, 0.31 0.002, 0.95 0.058, 0.076 0.013, 0.69 0.002, 0.96
p < 0.5 0.000, 0.99 0.049, 0.14 0.016, 0.64 0.066, 0.041a 0.027, 0.42 0.004, 0.90
p < 0.1 20.008, 0.82 0.031, 0.34 20.007, 0.83 0.038, 0.24 0.002, 0.96 20.024, 0.48
p < 0.05 0.004, 0.91 0.041, 0.20 0.000, 0.10 0.052, 0.11 0.010, 0.76 20.012, 0.71
p < 0.01 20.036, 0.27 20.019, 0.56 20.039, 0.24 20.024, 0.46 20.040, 0.22 20.029, 0.39
LVD
p < 0.8 20.031, 0.35 0.002, 0.94 20.015, 0.65 0.044, 0.18 20.004, 0.90 20.004, 0.90
p < 0.5 20.034, 0.30 0.002, 0.96 20.020, 0.54 0.24, 0.038 20.010, 0.76 20.012, 0.72
p < 0.1 20.040, 0.22 0.012, 0.71 20.019, 0.56 0.037, 0.26 20.009, 0.78 20.01, 0.77
p < 0.05 20.013, 0.69 0.032, 0.33 0.000, 0.10 0.027, 0.41 0.006, 0.87 20.016, 0.64
p < 0.01 20.018, 0.58 0.045, 0.17 0.011, 0.75 0.043, 0.19 0.017, 0.61 0.008, 0.82
CE
p < 0.8 0.020, 0.53 0.005, 0.94 20.020, 0.54 0.031, 0.35 20.011, 0.75 20.044, 0.20
p < 0.5 20.034, 0.30 0.002, 0.96 20.020, 0.54 0.038, 0.24 20.010, 0.76 20.012, 0.72
p < 0.1 0.060, 0.064 0.029, 0.37 0.029, 0.38 0.064, 0.048a 0.038, 0.25 20.004, 0.90
p < 0.05 0.064, 0.048a 0.039, 0.24 0.033, 0.32 0.037, 0.26 0.035, 0.28 20.002, 0.96
p < 0.01 0.067, 0.039a 0.067, 0.040a 0.042, 0.19 0.062, 0.055 0.049, 0.13 0.002, 0.95
Abbreviations: CE 5 cardioembolic; g 5 general cognitive ability; gf 5 general fluid cognitive ability; IS 5 all ischemic stroke; LBC1936 5 Lothian Birth
Cohort 1936; LVD 5 large vessel disease; MHT 5 Moray House Test; NART 5 National Adult Reading Test; PGRS 5 polygenic risk score; SVD 5 small
vessel disease.
All analyses were corrected for 4 multidimensional scaling components and number of nonmissing genotypes used to calculate each risk score.
a Represents p values , 0.05.
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pathways, oxidative stress pathways, neurotransmitter
pathways,31 and, thereafter, individuals with lower
cognitive ability might be more likely to lead lifestyles
that predispose them to ischemic stroke. Finally, the
same genes may be influencing both risk of ischemic
stroke and cognitive ability through independent
pathways.
One strength of this study is the large population-
based cohort of GS. This allowed us to test the
hypothesis that high polygenic risk of ischemic stroke
is associated with lower cognitive ability even in the
absence of stroke. A limitation was that LBC1921
and LBC1936 are relatively small older cohorts.
Although the 3 cohorts consist of individuals born
in different time periods, we have twin- and family-
based and DNA-based evidence that the heritability
of cognitive ability is similar over these eras, and the
genetic variants influencing cognition will not have
changed during this time period.8,9,32 However, cog-
nitive ability in later life is an interaction between
genetics and environmental factors and each cohort
experienced very different situations, which may have
had an important influence on cognition, and hence,
may have influenced the results. All of the cohorts
were composed of largely healthy individuals, so the
effect sizes expected were small. A further limitation is
that we lacked information on incidental vascular
changes in the Scottish cohorts at the time of cogni-
tive testing. The results may have been driven by
individuals with undetected stroke. However, MRI
data are available for about 700 members of
LBC1936 at age 73 years (3 years after the cognitive
testing data used in this report were collected). At a
mean age of 73 years, as expected for an older popu-
lation, some white matter hyperintensities were evi-
dent in 97% of LBC1936. However, only 11% of the
Table 2 Correlations and significance between ischemic stroke (and its subtypes) PGRS (calculated using different association p values) and
cognitive phenotypes in LBC1921
Stroke PGRS
MHT (age 11 yr)
(n 5 464), r, p
MHT (age 79 yr)
(n 5 511), r, p gf (n 5 505), r, p NART (n 5 515), r, p g (n 5 505), r, p
Cognitive change
(n 5 453), r, p
IS
p < 0.8 20.001, 0.99 20.093, 0.036a 20.068, 0.13 20.080, 0.071 20.082, 0.067 20.054, 0.26
p < 0.5 0.007, 0.89 20.066, 0.14 20.044, 0.32 20.060, 0.17 20.058, 0.20 20.035, 0.46
p < 0.1 20.005, 0.92 20.054, 0.23 20.033, 0.46 20.082, 0.063 20.054, 0.23 20.023, 0.63
p < 0.05 0.004, 0.94 20.032, 0.48 20.028, 0.53 20.047, 0.29 20.039, 0.38 20.033, 0.48
p < 0.01 0.028, 0.55 20.003, 0.95 20.021, 0.64 0.021, 0.65 20.010, 0.83 20.064, 0.18
SVD
p < 0.8 20.013, 0.78 20.046, 0.30 20.051, 0.25 20.057, 0.20 20.060, 0.18 20.049, 0.31
p < 0.5 20.024, 0.60 20.057, 0.20 20.057, 0.20 20.052, 0.24 20.063, 0.16 20.048, 0.31
p < 0.1 20.004, 0.94 20.033, 0.46 20.022, 0.62 20.011, 0.80 20.021, 0.64 20.030, 0.53
p < 0.05 0.024, 0.61 20.040, 0.37 20.037, 0.41 20.007, 0.87 20.031, 0.49 20.063, 0.18
p < 0.01 20.013, 0.78 20.083, 0.061 20.047, 0.29 20.011, 0.81 20.040, 0.38 20.048, 0.31
LVD
p < 0.8 0.001, 0.98 20.021, 0.63 0.007, 0.88 20.062, 0.16 20.014, 0.75 0.037, 0.43
p < 0.5 20.003, 0.96 20.025, 0.57 20.002, 0.97 20.061, 0.17 20.019, 0.66 0.034, 0.48
p < 0.1 0.000, 0.99 20.031, 0.48 20.011, 0.81 20.056, 0.21 20.026, 0.57 0.025, 0.60
p < 0.05 0.025, 0.59 0.010, 0.82 0.024, 0.59 20.009, 0.84 0.015, 0.74 0.034, 0.47
p < 0.01 20.002, 0.97 20.011, 0.80 20.010, 0.83 20.023, 0.60 20.015, 0.74 0.020, 0.67
CE
p < 0.8 20.020, 0.67 20.070, 0.12 20.061, 0.17 20.030, 0.50 20.064, 0.15 20.067, 0.16
p < 0.5 20.001, 0.98 20.058, 0.19 20.053, 0.23 20.016, 0.72 20.053, 0.24 20.067, 0.16
p < 0.1 0.035, 0.45 20.031, 0.48 20.020, 0.65 0.013, 0.77 20.017, 0.70 20.049, 0.31
p < 0.05 20.008, 0.86 20.058, 0.20 20.040, 0.38 20.027, 0.55 20.043, 0.34 20.035, 0.47
p < 0.01 20.029, 0.53 20.11, 0.014a 20.13, 0.003a 20.074, 0.095 20.13, 0.004 20.13, 0.008a
Abbreviations: CE 5 cardioembolic; g 5 general cognitive ability; gf 5 general fluid cognitive ability; IS 5 all ischemic stroke; LBC1921 5 Lothian Birth
Cohort 1921; LVD 5 large vessel disease; MHT 5 Moray House Test; NART 5 National Adult Reading Test; PGRS 5 polygenic risk score; SVD 5 small
vessel disease.
All analyses were corrected for 4 multidimensional scaling components and number of nonmissing genotypes used to calculate each risk score.
a Represents p values , 0.05.
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cohort did not self-report having had a stroke, but did
have imaging evidence of a stroke.30 Population-based
studies indicate that white matter hyperintensities
increase with age.33 Therefore, we expect that the
percentage of individuals with undetected stroke
and white matter hyperintensities will be lower in
LBC1936 at mean age 70 years and lower still in
GS, which has a mean age of 55 years, and slightly
higher in LBC1921 at mean age 79 years.
We have presented uncorrected p values as all cog-
nitive phenotypes are correlated (r range: 0.19–0.70,
p , 0.001; tables e-3–e-5), as are many of the poly-
genic risk scores (tables e-6–e-8). However, it is pos-
sible that some of the findings may be attributable to
type 1 error. Future studies on larger groups with
more cognitive decline—especially where that is sus-
pected to be of vascular origin—might show larger
effect sizes. In the future, it would be helpful to be
able to create subtype risk scores based on larger
numbers of accurately phenotyped ischemic stroke
patients.
The findings from this study indicate that even in
the absence of stroke, being at high polygenic risk of
ischemic stroke is associated with lower cognitive abil-
ity. This may be attributable to a genetic predisposi-
tion to defects in brain integrity or circulation, which
increases the risk of stroke or reduces resilience to
withstand the effect of ischemic triggers on brain
damage. Alternatively, the genes may be acting inde-
pendently to influence cognitive ability and stroke
risk through different pathways.
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